It is common for many types of cancer to show multifocal intraperitoneal dissemination and ascitic fluid accumulation with intense neovascularization. Angiogenesis, a vital physiologic process resulting in the formation of new blood vessels from preexisting ones, is essential for tumor growth beyond 1-2 mm in diameter. Angiogenesis provides oxygen and nutrients to tumors while eliminating metabolic waste products and potentially promoting metastasis in response to acidosis, hypoxia, and metabolic deficiency. Vascular endothelial growth factors (VEGFs) and angiopoietins (ANGPTs) activate specific tyrosine kinase receptors, such as VEGFR1, VEGFR-2, VEGFR-3 and TIE2, which are expressed on blood endothelial cells and have crucial roles in the tumor angiogenic switch.
One notable antiangiogenic treatment in clinical use is bevacizumab, the drug has been demonstrated to enhance the progression-free survival rate among many cancer patients. However, the emergence of excessive angiogenic factors beyond VEGFs can contribute to resistance to bevacizumab. Therefore, it is of critical importance to identify new angiogenesis-related genes (ARGs) that are specifically linked to tumor formation. Such a discovery could aid in distinguishing high-risk patients, provide more precise prognosis predictions and outcomes, encourage the development of innovative therapeutic strategies, and foster the creation of new antiangiogenic medications.
This Research Topic aims to deliver valuable insights regarding the development of novel cancer targets for tumor angiogenesis and the improvement of antiangiogenic therapies. It will focus on two aspects: identification of new targets of angiogenesis in tumors and elucidation of the mechanisms by which new drugs kill cancer cells. We welcome submissions of the following article types: Brief Research Report, Data Report, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Technology and Code, covering, but not limited to, the following subtopics:
1. Identification of innovative targeted drugs with potential therapeutic value for cancers, focusing on the inhibition of angiogenesis in vivo;
2. Exploration and identification of novel ARGs with specific relevance to cancer patients;
3. Elucidation of the molecular mechanisms underpinning angiogenesis-related pathways;
4. Research involving anti-angiogenic drugs such as bevacizumab, and clinical trials.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
It is common for many types of cancer to show multifocal intraperitoneal dissemination and ascitic fluid accumulation with intense neovascularization. Angiogenesis, a vital physiologic process resulting in the formation of new blood vessels from preexisting ones, is essential for tumor growth beyond 1-2 mm in diameter. Angiogenesis provides oxygen and nutrients to tumors while eliminating metabolic waste products and potentially promoting metastasis in response to acidosis, hypoxia, and metabolic deficiency. Vascular endothelial growth factors (VEGFs) and angiopoietins (ANGPTs) activate specific tyrosine kinase receptors, such as VEGFR1, VEGFR-2, VEGFR-3 and TIE2, which are expressed on blood endothelial cells and have crucial roles in the tumor angiogenic switch.
One notable antiangiogenic treatment in clinical use is bevacizumab, the drug has been demonstrated to enhance the progression-free survival rate among many cancer patients. However, the emergence of excessive angiogenic factors beyond VEGFs can contribute to resistance to bevacizumab. Therefore, it is of critical importance to identify new angiogenesis-related genes (ARGs) that are specifically linked to tumor formation. Such a discovery could aid in distinguishing high-risk patients, provide more precise prognosis predictions and outcomes, encourage the development of innovative therapeutic strategies, and foster the creation of new antiangiogenic medications.
This Research Topic aims to deliver valuable insights regarding the development of novel cancer targets for tumor angiogenesis and the improvement of antiangiogenic therapies. It will focus on two aspects: identification of new targets of angiogenesis in tumors and elucidation of the mechanisms by which new drugs kill cancer cells. We welcome submissions of the following article types: Brief Research Report, Data Report, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Technology and Code, covering, but not limited to, the following subtopics:
1. Identification of innovative targeted drugs with potential therapeutic value for cancers, focusing on the inhibition of angiogenesis in vivo;
2. Exploration and identification of novel ARGs with specific relevance to cancer patients;
3. Elucidation of the molecular mechanisms underpinning angiogenesis-related pathways;
4. Research involving anti-angiogenic drugs such as bevacizumab, and clinical trials.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
